Document is current
Any future updates will be listed below
-
Authors
Raineri, Silvia
Sherriff, Julia A.
Thompson, Kevin S. J.
Jones, Huw
Pfluger, Paul T.
Ilott, Nicholas E.
Mellor, Jane http://orcid.org/0000-0002-5196-3734
-
Funding
Funding for this research was provided by:
H2020 Marie Skłodowska-Curie Actions (Grant Agreement No. 675610 (Chromatin and Metabolism - ChroMe))
ChronosTherapeuticsLtd.
Biotechnology and Biological Sciences Research Council (BB/P00296X/1)
- License Information
-
More Information
Article History
Received: 11 June 2021
Accepted: 17 March 2022
First Online: 7 April 2022
Declarations
:
: Ethical approval for these animal experiments (project RNU1183) was obtained by the University of Nottingham (Project Licence No. 30/3208) for RenaSci Ltd., Nottingham, UK. Precise details of the animal handling protocols and experimental procedures involving the animals are given in the ARRIVE Essential 10: Compliance Questionnaire, in the methods sections and InternalRef removed.
: Not applicable.
: JM holds stock in Chronos Therapeutics Ltd., and acts as an advisor to and holds stock in Oxford Biodynamics plc and Sibelius Natural Products Ltd. HJ, JS and KT are current (HJ) or past employees of Chronos Therapeutic Ltd. None of these companies or their employees has any commercial interest in this study or the outcome. None of the other authors has any conflict of interest.
